Background: We aimed to mimic the ACTG 5257 trial, comparing raltegravir (RAL),
30

Introduction 32
Although newer drugs belonging to the integrase inhibitors class (raltegravir, dolutegravir 33 and elvitegravir) as well as newer generation non-nucleoside reverse transcriptase inhibitors 34 (NNRTI) (such as rilpivirine) are now the most commonly prescribed third agents in first-line 35 combination antiretroviral therapy (cART), darunavir/r (DRV/r) and atazanavir/r (ATV/r) are 36 still among the indicated alternative options in several treatment guidelines [1] [2] [3] . Indeed, 37 ritonavir-boosted protease inhibitors (PI/r)-containing regimens retain strong supporting 38 evidence of long-term clinical efficacy, and are still considered as first-line options in persons 39 with low adherence or in cases with missing drug resistance tests before starting cART, due to 40 their high genetic barrier [1] [2] [3] . 41
The ACTG 5257 trial has compared the efficacy and tolerability of three first-line regimens 42 including ATV/r, DRV/r or raltegravir (RAL), in combination with tenofovir/emtricitabine 43 (TDF/FTC) in 1,809 naïve subjects enrolled in clinical sites in the United States [4] . The trial 44 demonstrated similar virological potency of the three regimens, even in patients starting cART 45 at high viral load, and lower tolerability for ATV/r including regimens as compared to the other 46 two drugs and also lower tolerability for DRV/r as compared to RAL. 47
One limitation of the ACTG study is its open-label design, and people on ATV/r may have 48 been more prone to switch their regimen for elevate bilirubin levels or the fear of a sustained 49 elevation. Moreover, ACTG 5257 showed results up to 3 years from the date of regimens 50 initiation and longer terms estimates are currently lacking. 51
We therefore aimed to conduct an analysis similar to that of the ACTG 5257 trial, by 52 comparing the long-term durability and safety of first-line RAL-including regimens to therapies 53 including either DRV/r or ATV/r but using observational data. Our analysis also provides acomparison of the effectiveness of the regimens when used in HIV-infected persons seen in 55 routine clinical practice in Italy where, unlike the USA, there is no barrier to access to 56 treatment and care. 57
Methods 58
The ICONA Foundation Study 59
The Italian Cohort Naives Antinetrovirals (ICONA) Foundation Study is a multi-centre 60 observational study of HIV-1-infected patients set up in 1997, including 51 centres of 61
Infectious Diseases across Italy. Patients eligible to be included in the cohort are those starting 62 cART when they are naive to antiretrovirals, regardless of the reason for which they had never 63 been previously treated. Demographic (age, sex, risk factors for HIV, education, job, marital 64 status), clinical (all clinical events, both HIV and non HIV related) and laboratory data and 65 information on therapy (both HIV and non HIV) are collected and recorded using electronic 66 data collection and updated at any new event or at least twice a year [www.icona.org]. Details 67 of the study are described elsewhere [5] . 68
The ICONA Foundation study has been approved by IRB of all the participating centres. All 69 patients sign a consent form to participate in ICONA, in accordance with the ethical standards 70 of the committee on human experimentation and the Helsinki Declaration (1983 revision). The 71 estimated percentage of refusal to participate the study is 5-10%. 72
Patient population 73
All the patients from the ICONA Foundation cohort who started their first cART regimen after 74 and drug-drug interaction). 89
Study outcomes 90
The response to the initial regimens was compared according to the specific third drug started 91 with respect of a number of end-points. Our primary objective was to compare treatment failure 92 between the three regimens (RAL, DRV/r, ATV/r). The composite end-point of treatment 93 failure was defined as virological failure (confirmed HIV-RNA>200 copies/ml after 6 months 94 of therapy) or discontinuation of the third drug of the regimen for any reasons. Secondary end-95 pointes included: 96  virological failure 50: confirmed HIV-RNA >50 copies/mL after 6 months of therapy 97  discontinuation of DRV/r or ATV/r or RAL because of intolerance/toxicity. 98
Discontinuations of the NRTI backbones have been ignored in this analysis. 99
Mean CD4 change from baseline to 2 nd years of follow-up according to the third drug were also 100 analysed in a subset of the study population with complete CD4 count data. 101
Patients were followed up from date of starting one of the studied regimens (i.e. baseline) to the 102 first end-point event, November 15 th , 2017, death or loss to follow-up. 103
Statistical analyses 104
For the comparison of characteristics at time of treatment initiation among the three groups, 105
Chi-square or Kruskal-Wallis test were used as appropriate. Survival analysis with Kaplan-106
Meier curves were used and the probability of the outcome was estimated together with 95% 107 confidence interval for each time point. Log-rank test was used to test the equality of survival 108 curves. 109 We have used a cause-specific hazards for the survival analysis. This was done under the non-123 testable assumption that censoring due to virological failure is non informative (unrelated to) 124 for the risk of stopping a drug because of other reasons (e.g. toxicity or simplification). The median age at baseline was 40 years (IQR: 32-48), 21% were females, 22% migrants, 40% 139 men who acquired HIV through sex with other men (MSM); 224 (10%) were HCV coinfected 140 and 92 (4.1%) HBV coinfected. Median CD4 at treatment initiation was 277 cells/mmc (IQR: 141 120-415), the proportion of subjects with baseline CD4 <200 was 37%. Median HIV-RNA at 142 baseline was 4.9 log10 copies/mL (IQR: 4.3-5.4), 44% had a pre-treatment HIV-RNA 143 >100,000 copies/mL. 144
Patients on ATV/r-were less frequently males, less frequently Italian, more frequently HCV 145 coinfected and started cART in earlier calendar years than patients given either DRV/r or RAL. 146
Patients on DRV/r had the lowest median CD4 counts and highest median HIV-RNA copy 147 levels. Patients on RAL including regimens were more frequently affected by comorbidities 148 (24/241; 10%) than those initiating ATV/r (42/985; 4.3%) or DRV/r (52/1023; 5.1%) (p=.002). 149
Patients' characteristics according to the third drug are shown in Table 1 . 150
Participants have been followed-up for a median of 3.6 years from ART initiation 151 Finally, the 3 year-probability of treatment discontinuation due to toxicity was 21.7% 162 (95%CI: 18.9-24.9) for ATV/r, 13.7% (95%CI: 11.3-16.6) for DRV/r and 4.1% (95% CI: 2.0-163
The Kaplan Meier's curves of the risk of experiencing the various end-points, stratified for 165 regimen, are shown in Figure 1 . 166 167
A total of 627 patients (63.6%) discontinued ATV/r, 605 (59.1%) discontinued DRV/r 168 and 125 (51.9%) RAL. Discontinuation due to toxicity was the main cause of interruption in 169 patients on ATV/r (209 out of 627, 33.3%), while simplification was the main cause of 170 discontinuation both for patients on DRV/r (276 out of 605 discontinuations; 45.6%), and for 171 patients on RAL (59 out of 125 discontinuations, 47.2%) ( Table 2) . 172
The main cause of discontinuation were H hyperbilirubinemia for ATV/r, gastrointestinal 173 intolerance and lipid abnormalities for DRV/r. Only 10 patients on RAL discontinued for 174 toxicity, mainly due to allergic reactions, gastrointestinal complaints and nephrotoxicity (Table  175 2). 176 In detail, our estimates of the incidence of treatment failure according to the three 224 regimens were similar but not identical to those seen in the trial and showed a higher risk of 225 failure for patients starting ATV/r as compared to those initiating the other two regimens. In 226 fact, the absolute estimates of failure in our analysis were considerably higher than those 227 observed in the trial. However, in the trial the definition of treatment failure included 228 virological failure but only discontinuation of drugs due to toxicity/intolerance. We preferred to 229 use a broader definition of treatment failure including the discontinuations of the third drugs for 230 any reasons, given the observational setting of our study and the possible misclassifications of 231 reasons for discontinuation, and this might in part explain the higher frequency of treatment 232 failure in the Icona cohort as compared to that seen in the trial. . 233
Further, patients from the ICONA cohort were only partially comparable to US patients 235 enrolled in the ACTG trial: in ICONA, there were more subjects who acquired HIV infection 236 by intravenous drug use (8.6% vs 2%) and less subjects who were infected through men to men 237 sexual intercourse (39.7% vs 54% ) than in the ACTG trial, reflecting the known differences in 238 the HIV epidemics in Italy vs USA [4] . The different case mix and the real-life setting of the 239 ICONA patients, potentially enriched with a population of less adherent patients, might have 240 also contributed to the higher failure rates seen. . 241
The probability of discontinuation because of toxicity was higher in our cohort as 242 Further, in our analysis RAL appeared to be superior in terms of tolerability also, 249 although to a less extent, to DRV/r. These data are partly unexpected because patients on RAL 250
showed a higher frequency of comorbidities at treatment initiation. The possible toxic effect of 251 the drug is therefore difficult to disentangle from an apparent channelling bias [7] [8] [9] . This was 252 replicated in our multivariable analysis which, after controlling for baseline imbalances 253 between groups, showed identical results. 254
When we looked at pure virological failure, patients receiving RAL-including 255 combinations showed a 50% reduction in risk of failure as compared to those receiving DRV/r; 256 there was no evidence for a difference in virological failure when comparing the two PI/r 257 against each other. In contrast, the analysis of the trial shows no differences in the rate of 258 virological failure between the three arms regardless of the threshold chosen to define viral 259 failure (50 or 200 copies/mL). Because of the known limitation of adjusting for confounders bymultivariable analysis, we cannot rule out that the reduced risk of failure of RAL recipients in 261 our analysis was partly due to this imbalance at baseline. affected the higher probability of treatment failure and discontinuation for toxicity in our data 282 set as compared to previous ones. 283
Unexpectedly, we found that ATV/r given patients had a better 2-year CD4 recovery as 284 compared to other groups. In contrast, the trial shows a better immune recovery in the RAL 285 arm; there are a number of possible explanations for this discrepancy, including possibleselection bias, the relatively small numbers in the RAL group, and, of course, unmeasured 287 confounding. 288
Our study has several limitations: first, because this is not a randomised study, 289 channelling bias cannot be ruled out; indeed there was an imbalance between treatment arms 290 even in measured potential confounders: for example; RAL was more likely given to 291 participants with less advanced HIV diseases but with more comorbidities. Although we have 292 accounted for these difference in the multivariable analysis, residual confounding might exist. 293
The major strengths of our analysis are the real life composition of the study 294 population, the possibility to compare the treatment strategy in a setting with free-access to care 295 and the long-term follow-up (on average one year longer than the trial). Indeed, we believe that 296 the most important aspect of our analysis is that it was conducted in Italy so results should be 297 less affected by bias due to socio-economic factors limiting patients' adherence to expensive 298 treatment like in the USA trial setting. 299
In conclusion, our analysis shows higher absolute risks of failure for all regimens 300 studied compared to those estimated in the randomised comparison but this discrepancy is 301 largely attributable to the difference in the definition of the main endpoint used and the case-302 mix of the study population. More importantly, the analysis confirms in the real-life setting, the 303 lower tolerability and higher rate of discontinuation of ATV/r compared to DRV/r and RAL 304 observed in the trial. In addition, we found a clear signal that RAL might be superior to both 305 PI/r-based regimens with respect to tolerability and risk of virological failure with a threshold 306 of >50 copies/mL. 307
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